Who are Butylphthalide soft capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NeuroAiD, Butylphthalide Soft Capsules, Xaliproden (SR57746A), DMB-I (INN: Latrepirdine), Citicoline eye drops 2%, EGb761.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/butylphthalide-soft-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Butylphthalide soft capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Butylphthalide soft capsule (Butylphthalide soft capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent. Area: Neurology.

phase 3 Neuroprotective agent Mitochondrial function modulator (non-specific) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Butylphthalide soft capsule (Butylphthalide soft capsule) — Capital Medical University. Butylphthalide protects brain cells by improving mitochondrial function and reducing oxidative stress and inflammation following ischemic stroke.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Butylphthalide soft capsule TARGET	Butylphthalide soft capsule	Capital Medical University	phase 3	Neuroprotective agent	Mitochondrial function modulator (non-specific)
NeuroAiD	NeuroAiD	CHIMES Society	marketed	Herbal neuroprotective agent
Butylphthalide Soft Capsules	Butylphthalide Soft Capsules	Peking Union Medical College Hospital	marketed	Neuroprotective agent
Xaliproden (SR57746A)	Xaliproden (SR57746A)	Sanofi	phase 3	Neuroprotective agent	NMDA receptor
DMB-I (INN: Latrepirdine)	DMB-I (INN: Latrepirdine)	Bigespas LTD	phase 3	Neuroprotective agent	NMDA receptor, mitochondrial membrane, monoamine oxidase
Citicoline eye drops 2%	Citicoline eye drops 2%	Omikron Italia S.r.l.	phase 3	Neuroprotective agent / Membrane repair agent	Phospholipid synthesis pathway (CDP-choline pathway)
EGb761	EGb761	Ipsen	phase 3	Herbal extract / Neuroprotective agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent class)

Bigespas LTD · 1 drug in this class
Capital Medical University · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Rong Hu, MD · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Butylphthalide soft capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/butylphthalide-soft-capsule. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing